A time for celebration
The Lancet Infectious Diseases reaches a milestone this month: our 200th issue. This happy event gives us an opportunity to reflect on the journey that the journal has had and look back at what has happened in the field of infectious diseases over the past 17 years.
The first issue of The Lancet Infectious Diseases was published in August, 2001, and for the following years the journal published mostly reviews, personal views, news, and comments. It was only in August, 2010, that original research articles were published for the first time, giving the journal the opportunity to present in its pages the most recent advances in the field of infectious diseases. Reflecting the aim of all journals in The Lancet family to publish "Best science for better lives", over the years The Lancet Infectious Diseases has tried to cover the most urgent and relevant issues for clinicians working in infectious diseases control and treatment, while making sure that more neglected topics-such as fungal infections and sexually transmitted infections last year-received attention. The strong clinical focus of the journal reflects our enduring aim to enhance clinical practice, policy making, and research, with the ultimate goal of making a difference in the lives of those who suffer from or manage infectious diseases.
In the past 17 years, major advances have been made in the field in terms of new diagnostic tools, drugs, and vaccines. For example, the availability of genome sequencing methods has revolutionised the level of information that epidemiological studies can provide, with direct impact on clinical practice. An Article by Roberto Amato and colleagues in this issue shows how this change has impacted on malaria: whereas chloroquine resistance emerged undetected for years and was only confirmed long after it had already spread across Asia and Africa, the current ready availability of genome sequencing allows real-time monitoring of the emergent resistance to artemisinin and piperaquine and could be a key factor to limit its spread.
Another area where progress in research, advocacy, and service delivery has really changed the face of a disease in the first part of this century has been HIV. Since 2001, the prognosis for people living with HIV has changed substantially, thanks to the availability of new drugs, the introduction of treatment as prevention and, more recently, pre-exposure prophylaxis, as well as the expansion of diagnosis of the infection. In 2001, only about 700 000 people living with HIV had access to treatment, whereas in 2017 there were 21 million people with access to antiretroviral drugs. The commitment of The Lancet Infectious Diseases to expand its content on advances in research on HIV led in 2014 to the successful launch of The Lancet HIV.
During the lifetime of The Lancet Infectious Diseases, major outbreaks of infectious diseases have occurred: severe acute respiratory syndrome (2002), the H1N1 influenza pandemic (2009), Ebola virus disease (2014), and Zika virus infection (2015) . The last two outbreaks were particularly surprising for different reasons: the Ebola virus disease outbreak in west Africa unearthed deficiencies in the global response to outbreaks, but was also an opportunity for an unprecedented effort to rapidly develop control tools, such as vaccines; on the other hand, the outbreak of Zika virus infection in Latin America and its association with cases of microcephaly, concentrated mainly in north-east Brazil, was largely unexpected and has puzzled the medical community.
Over the years, the fight against growing antimicrobial resistance, which is threatening the ability to treat bacterial diseases has moved onto the global political agenda. Our journal has been at the forefront of disseminating research in this field with the publication of the first epidemiological study of carbapenem resistance mechanism NDM-1 in 2010 and the first report of plasmid-mediated resistance to colistin in 2016.
The Lancet Infectious Diseases would not have reached its 200th issue in such a strong position among journals in infectious diseases without the contribution of thousands of authors and peer reviewers, and members of the International Advisory Board. Thanks to their efforts and commitment, we are proud of what we publish every month and are confident that we can continue to contribute to the work of clinicians and the lives of patients. In a world where globalisation and shifting priorities challenge the control of infectious diseases, the journey ahead to continue to publish the best science looks both daunting and exciting. We are looking forward to continuing to share it with you.
